Avoro Capital Advisors’s Ultragenyx Pharmaceutical RARE Stock Holding History

Avoro Capital Advisors’s Portfolio RARE Stock Details RARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-330,000	Closed	-$12M	–	35
2025 Q2	$12M	Sell	330,000 -500,000	-60%	-$18M	0.21%	29
2025 Q1	$30.1M	Hold	830,000	–	–	0.47%	27
2024 Q4	$34.9M	Hold	830,000	–	–	0.49%	27
2024 Q3	$46.1M	Hold	830,000	–	–	0.67%	26
2024 Q2	$34.1M	Hold	830,000	–	–	0.45%	32
2024 Q1	$38.8M	Buy	830,000 +480,000	+137%	+$22.6M	0.45%	37
2023 Q4	$16.7M	Sell	350,000 -1,150,000	-77%	-$44.6M	0.23%	38
2023 Q3	$53.5M	Buy	1,500,000 +750,000	+100%	+$29.7M	0.83%	20
2023 Q2	$34.6M	Hold	750,000	–	–	0.47%	26
2023 Q1	$30.1M	Hold	750,000	–	–	0.45%	28
2022 Q4	$34.7M	Hold	750,000	–	–	0.52%	28
2022 Q3	$31.1M	Hold	750,000	–	–	0.57%	26
2022 Q2	$44.7M	Buy	750,000 +520,000	+226%	+$32M	0.88%	20
2022 Q1	$16.7M	Buy	+230,000	New	+$16M	0.3%	35

Other funds holding RARE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Avoro Capital Advisors's RARE Position: Q3 2025 in Review

Avoro Capital Advisors sold out of Ultragenyx Pharmaceutical (RARE) in Q3 2025, closing a stake of 330,000 shares — an estimated $12M sold.

Avoro Capital Advisors first reported a position in RARE in Q1 2022 and held it in 14 quarters. The position peaked at $53.5M in Q3 2023. 302 funds tracked by Wall St. Rank hold RARE as of Q3 2025.

Avoro Capital Advisors reported no remaining Ultragenyx Pharmaceutical position as of Q3 2025 after selling out during the quarter.
Avoro Capital Advisors sold 330,000 Ultragenyx Pharmaceutical shares in Q3 2025, an estimated $12M.
Avoro Capital Advisors first reported a position in Ultragenyx Pharmaceutical in Q1 2022 and held it in 14 quarters.
Avoro Capital Advisors's Ultragenyx Pharmaceutical position peaked at $53.5M in Q3 2023.
302 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q3 2025.

Based on Avoro Capital Advisors's 13F filing for Q3 2025, filed 14 Nov 2025.